Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00715780
First received: July 14, 2008
Last updated: November 4, 2016
Last verified: November 2016
  Purpose
This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes and other adverse events, and to evaluate efficacy while using insulin under normal clinical practice conditions. The switch from OAD treatment to insulin therapy will be determined by physician.

Condition Intervention
Diabetes
Diabetes Mellitus, Type 2
Drug: soluble human insulin
Drug: biphasic human insulin
Drug: insulin NPH
Drug: insulin aspart
Drug: biphasic insulin aspart
Drug: insulin detemir

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Safety and Efficacy Study in Subjects Using Insulin for the Treatment of Type 2 Diabetes Mellitus Failing on Oral Anti-diabetic Agents

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Incidence of major hypoglycaemic episodes [ Time Frame: during 26 weeks of insulin therapy ]

Secondary Outcome Measures:
  • Frequency and type of hypoglycaemic episodes [ Time Frame: during 26 weeks of insulin therapy ]
  • Frequency and type of adverse events [ Time Frame: during 26 weeks of insulin therapy ]
  • Frequency and type of adverse drug reactions [ Time Frame: during 26 weeks of insulin therapy ]
  • Change in HbA1c from baseline [ Time Frame: during 26 weeks of insulin therapy ]
  • Change in PPG from baseline [ Time Frame: during 26 weeks of insulin therapy ]
  • Change in FPG from baseline [ Time Frame: during 26 weeks of insulin therapy ]
  • Subjects' insulin treatment satisfaction [ Time Frame: during 26 weeks of insulin therapy ]
  • Physicians' satisfaction with insulin therapy [ Time Frame: during 26 weeks of insulin therapy ]
  • Weight change [ Time Frame: at the end of the study ]
  • Percentage of patients reaching the target of HbA1c less than 7.5% [ Time Frame: at the end of the study ]
  • Percentage of patients reaching the target of HbA1c less than 7% [ Time Frame: at the end of the study ]
  • Percentage of patients reaching the target of HbA1c less than 6.5% [ Time Frame: at the end of the study ]

Enrollment: 1667
Study Start Date: June 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
A Drug: soluble human insulin
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Other Name: Actrapid®
Drug: biphasic human insulin
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Drug: insulin NPH
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Drug: insulin aspart
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Drug: biphasic insulin aspart
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Drug: insulin detemir
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Type 2 diabetic patients
Criteria

Inclusion Criteria:

  • Type 2 diabetes for at least 12 months and currently receiving oral anti-diabetic (OAD) treatment, whether single or combination, for at least 3 months before this study
  • Insulin naive
  • Poor glycaemic control on OADs and decided by the physician to start insulin therapy

Exclusion Criteria:

  • Type 1 diabetes patients
  • Patients who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit
  • Patients with a hypersensitivity to insulin or to any of the excipients
  • Patient groups not approved in the product label
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00715780

Locations
Indonesia
Novo Nordisk Investigational Site
Jakarta, Indonesia, 12520
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00715780     History of Changes
Other Study ID Numbers: INS-3615
Study First Received: July 14, 2008
Last Updated: November 4, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin degludec, insulin aspart drug combination
Isophane insulin, beef
Insulin
Insulin Aspart
Insulin, Long-Acting
Hypoglycemic Agents
Isophane Insulin, Human
Insulin, Isophane
Insulin Detemir
Biphasic Insulins
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2017